Jevtana FDA Approval History
FDA Approved: Yes (First approved June 17, 2010)
Brand name: Jevtana
Generic name: cabazitaxel
Dosage form: Injection
Company: Sanofi
Treatment for: Prostate Cancer
Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Development timeline for Jevtana
| Date | Article |
|---|---|
| Jun 17, 2010 | Approval Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
